

ॐ Omkar Pharmachem Ltd.

Date: 29/05/2025

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Outcome of the Board Meeting held on 29th May, 2025

Company Scrip Code: 532167

Dear Sir,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 29th May, 2025 has considered and approved the following business:

1. Audited Financial Results of the Company for the quarter and year ended on 31st March, 2025.
2. Appointment of M/s. Maulik Bhavsar and Associates, Company Secretaries, having C.P. No. 11591, as Secretarial Auditor of the Company for a period of five consecutive years commencing from FY 2025-26 till FY 2029-30 subject to the approval of shareholders at the ensuing Annual General Meeting.

Details as required in terms of Regulation 30 of the Listing Regulations, as amended, read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure A.

The aforesaid board meeting commenced at 04:15 P.M. and concluded at 05:00 P.M.

This is for your information and record.

Thanking You,

Yours faithfully,
For Omkar Pharmachem Limited




Bhawani Shankar Goyal

(Managing Director)

DIN: 03255804

Address: House No. - 155/2, First Floor, Gali No - 2

Near Gurudwara, Govindpuri, Kalkaji- 110019

Delhi

Enc: a/a

INDEPENDENT AUDITORS' REPORT

**TO
THE BOARD OF DIRECTORS
OF OMKAR PHARMACHEM LIMITED**

**REPORT ON THE AUDIT OF THE STANDALONE FINANCIAL RESULTS OF
OMKAR PHARMACHEM LIMITED ("the Company")**

Opinion


We have audited the accompanying standalone financial results of **Omkar Pharmachem Limited** ("the company") for the quarter and year ended 31st March, 2025 (refer "Other Matter" section below), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results for the year ended on 31st March 2025:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the company for the year ended on 31st March, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and



the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Management and Board of Directors for the statement

The standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit, total comprehensive income and other financial information of the Company for the year ended on 31st March 2025 in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.


This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.




As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on complete set of financial statements on whether the company has adequate financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The statement includes results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year which were subjected to a limited review by us, as required under the LODR Regulations. Our opinion on the Statement is not modified in respect of this matter.

Date: 29/05/2025
Place: Ahmedabad

For Dipal R. Shah & Co.
Chartered Accountants
FRN 126576W



Dipal R. Shah
(Dipal R. Shah)
Partner

Mem. No. 119628


UDIN: 25119628BMGJNK4209

ॐ Omkar Pharmachem Ltd.

Statement of Standalone Audited Financial Results for the Quarter and Year ended 31st March, 2025

(Rs. in lakh except per share data)

Sr. No.	Particulars	Quarter Ended on			Financial Year ended on	
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Part-I						
1	Income from operations					
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	13.50	13.50	13.50	54.00	54.00
		13.50	13.50	13.50	54.00	54.00
2	Other Income	0.00	0.22	0.35	0.22	0.35
3	Net Total income	13.50	13.72	13.85	54.22	54.35
4	Expenses					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	4.72	4.20	3.63	16.07	15.79
	e) Finance Costs	1.71	0.00	2.91	1.71	2.91
	f) Depreciation and Amortization Expenses	0.15	0.15	0.14	0.51	0.49
	g) Other Expenses	2.16	0.88	2.39	8.93	9.88
	Total Expenses	8.74	5.23	9.07	27.22	29.07
5	Profit(Loss) before exceptional items and tax(3-4)	4.76	8.49	4.78	27.00	25.28
6	Exceptional items	0.00	0.00	0.00	0.00	0.00
7	Profit(Loss) before Tax(5+6)	4.76	8.49	4.78	27.00	25.28
8	Tax Expense	6.91	0.00	6.37	6.91	6.37
9	Profit(Loss) for the period (7-8)	(2.15)	8.49	(1.59)	20.09	18.91
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period (9+10)	(2.15)	8.49	(1.59)	20.09	18.91
12	Paid up Equity Share Capital (Face Value Rs. 10/-each)	1008.37	1008.37	1008.37	1008.37	1008.37
13	Other equity	(65.00)		(85.09)	(65.00)	(85.09)
14	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs.	(0.0213)	0.0842	(0.0158)	0.1992	0.1875



ॐ Omkar Pharmachem Ltd.

Statement of Assets and Liabilities		(Rs. in lakh)	
Sr. No	Particulars	As at 31-03-2025	As at 31-03-2024
		(Audited)	(Audited)
	ASSETS		
	Non-current Assets		
	a) Property, plant and equipment	0.70	0.81
	b) Capital work-in-progress	0.00	0.00
	c) Goodwill on consolidation	0.00	0.00
	d) Other intangible assets	0.00	0.00
	e) Intangible assets under development	0.00	0.00
	f) Financial assets	0.00	0.00
	i) Investments		
	a) Investment in associate	0.00	0.00
	b) Investments in joint ventures	0.00	0.00
	c) Other Investments	930.00	930.00
	ii) Other Financial Assets	0.00	0.00
	g) Deferred tax assets (net)	3.12	10.02
	h) Other non current assets	0.00	0.00
	Total Non-current Assets	933.82	940.83
	Current Assets		
	a) Inventories	0.00	0.00
	b) Financial assets		
	i) Other Investments	0.00	0.00
	ii) Trade receivables	9.72	4.76
	iii) Cash and cash equivalents	10.94	7.16
	iv) Bank balances other than iii) above	0.00	0.00
	v) Other financial assets	0.00	0.00
	c) Other current assets	5.85	6.49
	Total Current Assets	26.51	18.41
	Total Assets	960.33	959.24
	EQUITY AND LIABILITIES		
	Equity		
	a) Equity share capital	1008.37	1008.37
	b) Other equity : Reserve and Surplus	(65.00)	(85.09)
	Equity attributable to the owners of the company	943.37	923.28
	Non-controlling interests	0.00	0.00
	Total Equity	943.37	923.28
	Non-current liabilities		
	Financial liabilities		
	a) Borrowings	0.00	0.00
	b) Provisions	0.00	0.43
	c) Deferred tax liabilities(Net)	0.00	0.00
	Total Non-current Liabilities	0.00	0.43
	Current Liabilities		
	a) Financial liabilities		
	i) Borrowings	11.85	30.31
	ii) Trade Payables	0.99	1.77
	iii) Other financial liabilities	0.00	0.00
	b) Provisions	0.00	0.00
	c) Other current liabilities	4.12	3.45
	Total-current Liabilities	16.96	35.53
	Total Liabilities	16.96	35.96
	Total Equity and Liabilities	960.33	959.24




ॐ Omkar Pharmachem Ltd.

Audited Cash flow statement for the year ended on 31st March, 2025		(Rs. in lakh)
Particulars	Financial year ended on 31-03-2025	Financial year ended on 31-03-2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and exceptional items	27.00	25.28
Adjustment For :		
Bad debts writtenoff	0.00	0.00
Depreciation	0.51	0.49
Net interest paid (received)	1.71	2.91
Operating profit before working capital change	29.22	28.68
Adjustment For :		
Trade and other receivables	(4.32)	1.71
Trade and other payable	(0.55)	(0.83)
Cash Generated from operation	24.35	29.56
Cash flow before extra ordinary items	0.00	0.00
(Less) IncomeTaxPaid including AdvanceTax/TDS less refund	0.00	0.00
Net Cash Flow From Operating Activities	24.35	29.56
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of Property, plant and equipment (Land)	0.00	0.00
Sale of Investment	0.00	0.00
Purchase of Property, plant and equipment	(0.40)	(0.93)
Net Cash Used In Investing Activities	(0.40)	(0.93)
C. CASH FLOW FROM FINANCIAL ACTIVITIES		
Interest received/(paid)	(1.71)	(2.91)
Short Term Borrowings (Net)	(18.46)	(31.83)
Net Cash Flow From Financial Activities	(20.17)	(34.74)
Total Cash Flow	3.78	(6.11)
Net Increase/Decrease In Cash And Cash Equivalents :		
Opening Cash and Cash Equivalents	7.16	13.27
Closing Cash and Cash Equivalents	10.94	7.16
Net Increase/Decrease In Cash And Cash Equivalents	3.78	(6.11)

Notes:

1. The above results have been reviewed by the audit committee & approved by the Board of Directors at their respective meeting held on 29-05-2025
2. Corrospounding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
3. The financial result for the quarter and year ended on 31st March 2025 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
4. The IND-AS regarding segment reporting is not applicable to the company.
5. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter of the current financial year.

By order of the Board



(Bhawani Shankar Goyal)

Managing Director

DIN No. 03255804

House No. - 155/2, First Floor, Gali No - 2, Near
Gurudwara, Govindpuri, Kalkaji, Delhi-110019

Date : 29-05-2025

Place: Ahmedabad

ॐ Omkar Pharmachem Ltd.

Date: 29/05/2025

To,
B S E Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 532167

Sub: - Declaration under Regulation 33(3)(d) of the SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015.

Ref- Annual Audited Financial Results for the Quarter and year ended on 31st March 2025

DECLARATION

I, Bhawani Shankar Goyal, Managing Director of the **OMKAR PHARMACHEM LIMITED** (CIN:L93000GJ1995PLC025276) having its registered office at 310, Wall Street-1, Near Gujarat College Cross Road, Ellisbridge Ahmedabad-380006 Gujarat, hereby declare that, the Statutory Auditor of the Company i.e. **M/s. Dipal R. Shah & Co. (FRN: 126576W and M. No- 119628)** have issued an Audited Report with unmodified opinion on Audited Financial Results of the Company for the quarter and year ended on 31st March, 2025.

This Declaration is given in Compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your Records.

Thanking you,

Yours faithfully,
For Omkar Pharmachem Limited




Bhawani Shankar Goyal
(Managing Director)
DIN: 03255804

Address: House No. - 155/2, First Floor, Gali No - 2
Near Gurudwara, Govindpuri, Kalkaji- 110019
Delhi

Annexure-A

Disclosures required under Regulation 30 read with Schedule III of the SEBI Listing Regulations read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 is as follows:

Sr. No.	Particulars	Details
1.	Name of the Secretarial Auditor	M/s. Maulik Bhavsar and Associates, Company Secretaries
2.	Reason for Change	Due to Appointment
3.	Date of appointment	29.05.2025
4.	Term of appointment	The appointment is for a period of Five consecutive years commencing from FY 2025-26 till FY 2029-30
5.	Brief profile (in case of appointment)	M/s. Maulik Bhavsar and Associates, Company Secretaries is a Peer-Reviewed Firm of Practicing Company Secretaries based in Ahmedabad, established in 2012. Founded by CS Maulik Bhavsar, a member of the Institute of Company Secretaries of India, the firm specializes in Company Law, SEBI, FEMA, IPR, SME & Mainboard Listings, Agreement Drafting, Corporate Restructuring, Secretarial Audit, and Due Diligence. With a global clientele and a strong compliance track record, the firm is known for its expertise and commitment to professional excellence.
6.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

B/m

